0

Effect of Dilazep Dihydrochloride on Serum Cardiac Troponin T Levels in Hemodialysis Patients

Tsukasa Nakamura, Chifuyu Ushiyama, Shiwori Osada, Kazuya Ugai, Yutaka Takahashi, Araki Tanaka, Noriaki Shimada, Isao Ebihara, Hikaru Koide

Kidney Blood Press Res. 2002;25(1):50-4.

PMID: 11834877

Abstract:

Background/aim:
Cardiac troponin T is a highly sensitive marker for the detection of myocardial injury. We studied whether dilazep dihydrochloride affects cardiac troponin T levels in hemodialysis patients.
Methods:
Our study included 60 hemodialysis patients without symptoms of acute myocardial ischemia. We measured serum cardiac troponin T levels by the Elecsys troponin T assay and randomized 40 hemodialysis patients with left ventricular hypertrophy (LVH) into two treatment groups: a dilazep dihydrochloride group (300 mg/day, n = 20) and a placebo group (n = 20). Treatment was continued for 12 months.
Results:
There were no significant differences between pre- and postdialysis cardiac troponin T levels before treatment. LVH was noted in 40 patients out of 60 hemodialysis patients (67%). Cardiac troponin T levels were significantly higher in these patients (0.23 +/- 0.08 microg/l) than in hemodialysis patients without LVH (0.09 +/- 0.03 microg/l). Cardiac troponin T levels were reduced from 0.24 +/- 0.08 to 0.12 +/- 0.06 microg/l (p < 0.01) in patients treated with dilazep dihydrochloride. There were no change in cardiac troponin T levels in patients receiving placebo (from 0.21 +/- 0.08 at baseline to 0.20 +/- 0.07 microg/l).
Conclusion:
Dilazep dihydrochloride may be effective in ameliorating myocardial damage in hemodialysis patients.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP20153984 Dilazep dihydrochloride Dilazep dihydrochloride 20153-98-4 Price
qrcode